What’s New in Immunotherapy and Melanoma? [Webchat]

Cancer immunotherapy is a kind of cancer treatment that mobilizes the patient’s immune defenses to recognize and attack tumor cells. It is now the treatment of choice for many patients with advanced melanoma, according to Elizabeth I. Buchbinder, MD, a melanoma specialist at Dana-Farber.

“Immunotherapy has taken off,” Buchbinder says, “There are tons of areas where it is being developed, as well as some where it really has entered into the mainstream for cancer care.”

Buchbinder is interested in the potential of using immunotherapy to prevent reoccurrence of melanoma in patients.

“This is an area that’s very active right now,” Buchbinder says, “We’re really hopeful that we can use these drugs to lower the risk of melanoma coming back.”

Buchbinder discussed other developments in immunotherapy research and melanoma in a recent Facebook Live webchat. View the video below.

Learn more about melanoma treatment and research from the Center for Melanoma Oncology at Dana Farber/Brigham and Women’s Cancer Center.

Make An Appointment

For adults: 877-442-9599

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
RT @HarvardChanSPH: This morning we joined @harvardmed and @DanaFarber to stand up for science. #MarchForScience https://t.co/udwrE6XD0s
Dana-Farber @danafarber
Today, and every day, we stand up for science. #MarchforScienceBoston https://t.co/dWw0lshWGf
Dana-Farber @danafarber
Boston's ducklings are decked out for the #MarchforScience! @Mrch4ScienceBOS https://t.co/FMsMpZg1Rc

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.